Table 4.

PFAS compounds screened in this study and reported in published literature to disrupt mammalian thyroid hormone system in vivo.

			In vivo reference	Assays in which chemical was active (≥20% activity)
Name	Acronym	CASRN		hDIO1	hDIO2	hDIO3	hlYD	hTTR	hTBG	hTPO
Perfluorobutanesulfonic acid	PFBS	375-73-5	NTP, 2019	–a	–	–	–	Xb	–	–
Potassium perfluorobutanesulfonate	K-PFBS	29,420-49-3	Ladics et al., 2008	–	–	–	–	Xb	–	–
Potassium perfluorohexanesulfonate	K-PFHxS	3871-99-6	Ramhøj et al., 2020, Butenhoff et al., 2009a, b, Ramhøj et al., 2018	–	–	–	–	Xb	–	–
Perfluorooctanesulfonic acid	PFOS	1763-23-1	Dong et al., 2016	Xb	Xb	–	Xb	Xb	X	X
Potassium perfluorooctanesulfonate	PFOS-K	2795-39-3	Seacat et al., 2002, Chang et al., 2008, Thibodeaux et al., 2003, Lau et al., 2003, Yu et al., 2009, Yu et al., 2011, Chang et al., 2009, Martin et al., 2007, Curran et al., 2008, Luebker et al., 2005, Wang et al., 2011	Xb	Xb	–	Xb	Xb	X	X
Perfluorobutanoic acid	PFBA	375-22-4	Butenhoff et al., 2012	–	–	–	–	Xb	–	–
Perfluorohexanoic acid	PFHxA	307-24-4	NTP, 2019	–	–	–	–	Xb	–	–
Perfluorooctanoic acid	PFOA	335-67-1	NTP, 2019	–	X	–	X	Xb	X	–
Ammonium perfluorooctanoate	APFOA	3825-26-1	Martin et al., 2007, Butenhoff et al., 2002	–	–	–	X	Xb	X	–
Perfluorononanoic acid	PFNA	375-95-1	NTP, 2019	X	X	–	Xb	Xb	X	X
Perfluorodecanoic acid	PFDA	335-76-2	Gutshall et al., 1989, Langley and Pilcher, 1985, Van Rafelghem et al., 1987, NTP, 2019	Xb	Xb	Xb	Xb	Xb	X	–
Perfluorotetradecanoic acid	PFTEDA	376-06-7	Hirata-Koizumi., 2015	Xb	X	Xb	–	Xb	X	–
8:2 Fluorotelomer alcohol	8:2 FTOH	678-39-7	Ladics et al., 2008	–	X	–	–	–	–	–

Chemicals were deemed in vivo active if changes in hormone levels or thyroid gland histopathology were reported.

^aNot active (– -) in this screening study (<20% activity).

^b≥50% activity and EC50 could be calculated in concentration response testing.